These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34860970)

  • 1. Pharmacovigilance of Sodium-Glucose Cotransporter-2 Inhibitors for Genital Fungal Infections and Urinary Tract Infections: A Review of the Food and Drug Administration Adverse Event Reporting System Database.
    Mohammad H; Borja-Hart N
    J Pharm Technol; 2018 Aug; 34(4):144-148. PubMed ID: 34860970
    [No Abstract]   [Full Text] [Related]  

  • 2. Urinary tract infections and genital mycotic infections associated with SGLT‑2 inhibitors: an analysis of the FDA Adverse Event Reporting System.
    Yang T; Zhou Y; Cui Y
    Expert Opin Drug Saf; 2024 Aug; 23(8):1035-1040. PubMed ID: 38009230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Survey of the FDA's Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter-2 Inhibitor Use.
    Shen J; Yang J; Zhao B
    Diabetes Ther; 2019 Jun; 10(3):1043-1050. PubMed ID: 30953300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
    Li D; Wang T; Shen S; Fang Z; Dong Y; Tang H
    Diabetes Obes Metab; 2017 Mar; 19(3):348-355. PubMed ID: 27862830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database.
    Perlman A; Heyman SN; Matok I; Stokar J; Muszkat M; Szalat A
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1108-1113. PubMed ID: 29174031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System.
    Hu Y; Bai Z; Tang Y; Liu R; Zhao B; Gong J; Mei D
    J Diabetes Res; 2020; 2020():3695101. PubMed ID: 32695827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Sodium-Glucose Co-Transporter 2 Inhibitors.
    McGill JB; Subramanian S
    Am J Cardiol; 2019 Dec; 124 Suppl 1():S45-S52. PubMed ID: 31741440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.
    Stottlemyer BA; McDermott MC; Minogue MR; Gray MP; Boyce RD; Kane-Gill SL
    Ther Adv Drug Saf; 2023; 14():20420986231181334. PubMed ID: 37332887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
    Carlson CJ; Santamarina ML
    Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of New Oral Hypoglycemic Agents on Risk of Urinary Tract and Genital Infections in Type 2 Diabetes: A Network Meta-analysis.
    Wang M; Zhang X; Ni T; Wang Y; Wang X; Wu Y; Zhu Z; Li Q
    Adv Ther; 2021 Jun; 38(6):2840-2853. PubMed ID: 33999339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Events of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease: A Retrospective Chart Review.
    Choi H; Nguyen LA; Wan J; Milani H; McGill K; Park J
    Perm J; 2021 May; 25():. PubMed ID: 33970086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention and Management of Genital Mycotic Infections in the Setting of Sodium-Glucose Cotransporter 2 Inhibitors.
    Engelhardt K; Ferguson M; Rosselli JL
    Ann Pharmacother; 2021 Apr; 55(4):543-548. PubMed ID: 32808541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions.
    D'Elia JA; Segal AR; Bayliss GP; Weinrauch LA
    Int J Nephrol Renovasc Dis; 2017; 10():153-158. PubMed ID: 28670136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.
    Palapra H; Viswam SK; Kalaiselvan V; Undela K
    Int J Clin Pharm; 2022 Dec; 44(6):1425-1433. PubMed ID: 36224513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews.
    Pelletier R; Ng K; Alkabbani W; Labib Y; Mourad N; Gamble JM
    Ther Adv Drug Saf; 2021; 12():2042098621989134. PubMed ID: 33552467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans.
    Suzuki M; Hiramatsu M; Fukazawa M; Matsumoto M; Honda K; Suzuki Y; Kawabe Y
    Diabetes Obes Metab; 2014 Jul; 16(7):622-7. PubMed ID: 24400675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives.
    John M; Gopinath D; Jagesh R
    Indian J Endocrinol Metab; 2016; 20(1):22-31. PubMed ID: 26904465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
    Vivian EM
    Drugs Context; 2014; 3():212264. PubMed ID: 25598831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.
    Trujillo JM; Nuffer WA
    Pharmacotherapy; 2017 Apr; 37(4):481-491. PubMed ID: 28102030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit.
    Thong KY; Yadagiri M; Barnes DJ; Morris DS; Chowdhury TA; Chuah LL; Robinson AM; Bain SC; Adamson KA; Ryder REJ;
    Prim Care Diabetes; 2018 Feb; 12(1):45-50. PubMed ID: 28669625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.